ALKS Alkermes plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ALKS

Price (delayed)

$49.45

Market cap

$8.3B

P/E Ratio

123.63

Dividend/share

N/A

EPS

$0.4

Enterprise value

$9.36B

?
Relative Growth: Rel. Growth: 33
Relative Strength: Rel. Strength: 87
Relative Valuation: Rel. Valuation: 16
Relative Profitability: Rel. Profitability: 53

Alkermes plc, a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of ...

Highlights
The company's equity rose by 11% YoY and by 3.3% QoQ
The revenue has grown by 11% YoY and by 7% from the previous quarter
ALKS's quick ratio is down by 38% year-on-year but it is up by 10% since the previous quarter
ALKS's P/E is 144% above its last 4 quarters average of 50.6
Alkermes's net income has plunged by 81% YoY and by 57% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.alkermes.com
Peers: JNJ BMY NVS TEVA

Key stats

What are the main financial stats of ALKS

ALKS stock price

How has the Alkermes stock price performed over time
Intraday
-1.65%
1 week
2.23%
1 month
-4.67%
1 year
72.72%
YTD
76.73%
QTD
-5.62%

Financial performance

How have Alkermes's revenue and profit performed over time
Revenue
$1.67B
Gross profit
$1.41B
Operating income
$143.67M
Net income
$66.12M
Gross margin
84.6%
Net margin
4%
The net margin has plunged by 83% YoY and by 59% from the previous quarter
Alkermes's net income has plunged by 81% YoY and by 57% from the previous quarter
The company's operating margin has shrunk by 65% YoY and by 30% QoQ
Alkermes's operating income has plunged by 62% YoY and by 25% from the previous quarter

Price vs fundamentals

How does ALKS's price correlate with its fundamentals

Growth

What is Alkermes's growth rate over time

Valuation

What is Alkermes stock price valuation
ALKS P/E details
P/E
123.63
P/B
4.56
P/S
4.95
EV/EBIT
59.82
EV/EBITDA
42.91
EV/Sales
5.61
ALKS's P/E is 144% above its last 4 quarters average of 50.6
The EPS has dropped by 81% year-on-year and by 57% since the previous quarter
The P/B is 34% higher than the last 4 quarters average of 3.4 and 23% higher than the 5-year quarterly average of 3.7
The company's equity rose by 11% YoY and by 3.3% QoQ
ALKS's P/S is 41% above its 5-year quarterly average of 3.5 and 30% above its last 4 quarters average of 3.8
The revenue has grown by 11% YoY and by 7% from the previous quarter

Efficiency

How efficient is Alkermes business performance
The ROA has shrunk by 88% YoY and by 63% QoQ
The return on equity has dropped by 84% year-on-year and by 58% since the previous quarter
The ROIC has plunged by 72% YoY and by 45% from the previous quarter
The ROS has dropped by 66% year-on-year and by 38% since the previous quarter

Dividends

What is ALKS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALKS.

Financial health

How did Alkermes financials performed over time
Alkermes's total assets is 70% higher than its total liabilities
Alkermes's total assets has surged by 95% YoY and by 3.2% QoQ
ALKS's quick ratio is down by 38% year-on-year but it is up by 10% since the previous quarter
The debt is 13% less than the equity
The company's equity rose by 11% YoY and by 3.3% QoQ
The debt to equity is down by 3.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.